SECFilings.com helps investors track public company disclosures with smart tools and real-time alerts. Trusted by thousands of investors daily.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 11-K - Annual report of employee stock purchase, savings and similar plans
Form 11-K - Annual report of employee stock purchase, savings and similar plans
Form S-8 - Securities to be offered to employees in employee benefit plans
Form 8-K - Current report - Item 5.02 Item 5.07
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 5.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form S-8 - Securities to be offered to employees in employee benefit plans
Form 8-K - Current report - Item 2.01 Item 2.03 Item 7.01 Item 9.01
Form 8-K - Current report - Item 8.01
Form 8-K - Current report - Item 8.01
Form 8-K - Current report - Item 8.01
Form 8-K - Current report - Item 7.01 Item 8.01 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 5.02
Form 8-K - Current report - Item 2.02 Item 9.01
Form 11-K - Annual report of employee stock purchase, savings and similar plans
Form 11-K - Annual report of employee stock purchase, savings and similar plans
Form 8-K - Current report - Item 8.01
Form 8-K - Current report - Item 5.07
Form 8-K - Current report - Item 8.01
Form 8-K - Current report - Item 7.01 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 1.01 Item 1.02 Item 9.01
Form 8-K - Current report - Item 1.01 Item 9.01
Form 8-K - Current report - Item 1.01 Item 9.01
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 1.01 Item 2.02 Item 8.01 Item 9.01
Form 8-K - Current report - Item 1.01 Item 2.03 Item 9.01
Form 8-K - Current report - Item 1.01 Item 2.03 Item 7.01 Item 9.01
Form 8-K - Current report - Item 7.01 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 7.01 Item 9.01
Form 8-K - Current report - Item 1.01 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 1.01 Item 7.01 Item 9.01
Form 8-K - Current report - Item 5.02 Item 9.01